Purine nucleoside phosphorylases: Properties, functions, and clinical aspects

Pharmacology and Therapeutics

Volumn 88, Issue 3, 2000, Pages 349-425

  Bzowska, Agnieszka ^a   Kulikowska, Ewa ^a   Shugar, David ^a,b  

^a UNIVERSITY OF WARSAW   (Poland)

^b INSTITUTE OF BIOCHEMISTRY AND BIOPHYSICS   (Poland)

Author keywords

Classification; Clinical aspects; Functions; Gene therapy; Inhibitors; Purine nucleoside phosphorylase; Specificities; Structures

Indexed keywords

PURINE NUCLEOSIDE PHOSPHORYLASE;

AMINO ACID SEQUENCE; B LYMPHOCYTE; BINDING AFFINITY; BONE MARROW TRANSPLANTATION; ENZYME DEFICIENCY; ENZYME REPLACEMENT; ENZYME SPECIFICITY; EUKARYOTE; GRAFT REJECTION; HUMAN; KINETICS; LIGAND BINDING; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROKARYOTE; REVIEW; SOLID STATE; STOICHIOMETRY; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANIMALS; BIOLOGICAL ASSAY; CATALYSIS; GENE THERAPY; HUMANS; KINETICS; MOLECULAR SEQUENCE DATA; NUCLEOSIDES; POINT MUTATION; PROTEIN CONFORMATION; PURINE-NUCLEOSIDE PHOSPHORYLASE;

EID: 0034452004     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(00)00097-8     Document Type: Review

References (405)

1. Deoxyribosyl exchange activity associated with nucleoside phosphorylase
2. Purine nucleoside phosphorylase from human erythrocytes: A kinetic study of the fully separated isoenzymes
3. Determination of purine enzyme activities in human erythrocytes by capillary electrophoresis
4. Determination of purine enzyme activities in human erythrocytes by capillary electrophoresis
5. Capillary electrophoresis for detection of inherited disorders of purine and pyrimidine metabolism
6. Purine nucleoside phosphorylase from human erythrocytes. Crystallization and some properties
7. Purine nucleoside phosphorylase. Microheterogenity and comparison of kinetic behaviour of the enzyme from several tissues and species
8. Fighting parasites on a shoestring
9. Stable and inheritable changes in genotype and phenotype of albino melanocytes induced by an RNA-DNA oligonucleotide
10. Genomic sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
11. Gapped BLAST and PSI-BLAST: A new generation of protein database search programs
12. Lentiviral vectors - The promise of gene therapy within reach?
13. The structure of human 5′-deoxy-5′-methylthioadenosine phosphorylase at 1.7 Å resolution provides insights into substrate binding and catalysis
14. Mitochondrial basis for immune deficiency: Evidence from purine nucleoside phosphorylase-deficient mice
15. Purine metabolism enzymes and immunological phenotype in chronic B-cell malignancies: Chronic lymphocytic leukemia, prolymphocytic leukemia and hairy cell leukemia
16. A continuous fluorimetric assay for ATPase activity
17. In vivo and in vitro pharmacologic activity of the purine nucleoside phosphorylase inhibitor BCX-34: The role of GTP and dGTP
18. Guanine, pyrazolo[3,4-d]pyrimidine, and triazolo[4,5-d]pyrimidine (8-azaguanine) phosphonate acyclic derivatives as inhibitors of purine nucleoside phosphorylase
19. Prolongation of skin graft survival in dogs treated with 8-aminoguanosine
20. Purine nucleoside phosphorylase inhibitors: Biochemical and pharmacological studies with 9-benzyl-9-deazaguanine and related compounds
21. Efficacy of pyrazolopyrimidine ribonucleosides against Trypanosoma cruzi: Studies in vitro and in vivo with sensitive and resistant strains
22. Purine and pyrimidine metabolism
23. Isolation of hexameric form of purine nucleoside phosphorylase from E. coli. Comparative study of trimeric and hexameric form of the enzyme
24. Purine pathway enzymes in the circulating malignant cells of patients with cutaneous T-cell lymphoma
25. Evidence for a pathway independent from 2′-deoxyguanosine and reversible by IL-2 by which purine nucleoside phosphorylase inhibitors block T-cell proliferation
26. Evaluation of purine nucleoside phosphorylase release as a measure of hepatic endothelial cell injury
27. Rational design of enzyme inhibitors: Multisubstrate analogue inhibitors
28. Correction of purine nucleoside phosphorylase deficiency by transplantation of allogeneic bone marrow from a sibling
29. Bone marrow transplantation in primary immunodeficiency
30. Gene therapy for human SCID: Dreams become reality
31. Drugs by design
32. Complete genome sequence of the methanogenic archaeon, Methanococcus jannaschii
33. Novel 6-alkoxypurine 2′,3′-dideoxy nucleosides as inhibitors of the cytopathic effects of the human immunodeficiency virus
34. A second purine nucleoside phophorylase in Escherichia coli K-12: II. Xanthosine phosphorylase mutants isolated as secondary-site revertants of a deoD mutant
35. 2-Chloro-2′-deoxyadenosine (cladribine) and its analogues are good substrates and potent selective inhibitors of Escherichia coli purine nucleoside phosphorylase
36. Purine nucleoside phosphorylase. Structure-activity relationships for substrate and inhibitor properties of N-1-, N-7-, and C-8-substituted analogues: Differentiation of mammalian and bacterial enzymes with N-1-methylinosine and guanosine
37. Properties of purine nucleoside phosphorylase (PNP) of mammalian and bacterial origin
38. Acyclonucleoside analogue inhibitors of mammalian purine nucleoside phosphorylase
39. Formycins A and B and some analogues: Selective inhibitors of bacterial (Escherichia coli) purine nucleoside phosphorylase
40. Linear free energy relationships for N(7)-substituted guanosines as substrates for calf spleen purine nucleoside phosphorylase. Possible role of N(7)-protonation as an intermediary in phosphorolysis
41. Purine nucleoside phosphorylase: Inhibition by purine N(7)- and N(9)-acyclonucleosides; and substrate properties of 7-β-d-ribofuranosylguanine and 7-β-d-ribofuranosylhypoxanthine
42. Calf spleen purine nucleoside phosphorylase: Purification, sequence and crystal structure of its complex with an N(7)-acycloguanosine inhibitor
43. Substrate/inhibitor properties of tumour purine nucleoside phosphorylase
44. Kinetics of phosphorolysis of 3-(β-d-ribofuranosyl)adenine and 3-(β-d-ribofuranosyl)hypoxanthine, non-conventional substrates of purine-nucleoside phosphorylase
45. 7-Deazapurine-2′-deoxyfuranosides are noncleavable competitive inhibitors of Escherichia coli purine nucleoside phosphorylase
46. Crystallization and preliminary X-ray studies of purine nucleoside phosphorylase from Cellulomonas sp
47. Synthesis of 6-aryloxy- and 6-arylalkoxy-2-chloropurines and their interactions with purine nucleoside phosphorylase (PNP) from Escherichia coli
48. Purification and characterization of extremely thermophilic and thermostable 5′-methylthioadenosine phosphorylase from the archaeon Sulfolobus solfataricus: Purine nucleoside phosphorylase activity and evidence for intersubunit disulfide bonds
49. Extremely thermophilic and thermostable 5′-methylthioadenosine phosphorylase from the archaeon Sulfolobus solfataricus: Gene cloning and amino acid sequence determination
50. Heterologous expression of 5′-methylthioadenosine phosphorylase from the archaeon Sulfolobus solfataricus: Characterization of the recombinant protein and involvement of disulfide bonds in thermophilicity and thermostability
51. In vitro assessment salvage pathways for pyrimidine bases in rat liver and brain
52. Thyroid purine nucleoside phosphorylase: II. Kinetic model by alternative substrate and inhibition studies
53. Late diagnosis and correction of purine nucleoside phosphorylase deficiency with allogeneic bone marrow transplantation
54. Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: Possible role of nucleoside kinase(s)
55. Substrate specificities of adenosine deaminase and adenosine phosphorylase from Bacillus cereus
56. Facile synthesis of 5′-deoxy- and 2′,5′-dideoxy-6-thiopurine nucleosides by nucleoside phosphorylases
57. A new isotopic assay for purine nucleoside phosphorylase
58. Purine nucleoside phoshorylase-catalyzed, phosphate-independent hydrolysis of 2-amino-6-mercapto-7-methylpurine ribonucleoside
59. A continuous spectrophotometric assay for protein phosphatases
60. Partial purification and characterization of purine nucleoside phosphorylase in Saccharomyces cerisiae
61. Kinetic analysis of purine nucleoside phosphorylase in Saccharomyces cerevisiae
62. Purification and characterization of purine nucleoside phosphorylase in Micrococcus luteus
63. Catalytic mechanism and inhibition studies of purine nucleoside phosphorylase (PNP) in Micrococcus luteus
64. Purification and partial characterization of purine nucleoside phosphorylase from Serratia marcescens
65. 5-Iodoribose 1-phosphate, an analog of ribose 1-phosphate. Enzymatic synthesis and kinetic studies with enzymes of purine, pyrimidine, and sugar phosphate metabolism
66. A new colorimetric assay for purine nucleoside phosphorylase
67. The kinetics of enzyme-catalyzed reactions with two or more substrates: II. Nomenclature and rate equations
68. Would suicide gene therapy solve the 'T-cell dilemma' of allogeneic bone marrow transplantation?
69. Correction of the mutation responsible for sickle-cell anemia by an RNA-DNA oligonucleotide
70. Effects of a novel purine nucleoside phosphorylase inhibitor, BCX-34, on activation and proliferation of normal human lymphoid cells
71. Crystallization and preliminary X-ray investigation of purine nucleoside phosphorylase from Escherichia coli
72. Diagnostic uses of the Hill (Logit and Nernst) plots
73. Gene therapy for cancer
74. Expression of human malaria parasite purine nucleoside phosphorylase in host enzyme-deficient erythrocyte culture
75. The complete genome of the hyperthermophilic bacterium Aquifex aeolicus
76. Antitumor potential of acyclic nucleoside phosphonates
77. Trypanosomal nucleoside hydrolase. A novel mechanism for the structure with a transition-state inhibitor
78. Enzymic determination of inorganic phosphates, organic phosphates and phosphate-liberating enzymes by use of nucleoside phosphorylase-xanthine oxidase (dehydrogenase)-coupled reactions
79. Rational design of quinazoline-based irreversible inhibitors of human erythrocyte purine nucleoside phosphorylase
80. Regioselective synthesis of imidazolo[4,5-g]quinazoline quinone nucleosides and quinazoline amino nucleosides. Studies of their xanthine oxidase and purine nucleoside phosphorylase substrate activity
81. The catalytic site of AMP nucleosidase. Substrate specificity and pH effects with AMP and formycin 5′-PO4
82. PD 141955 and CI-972: 9-deazaguanine analog purine nucleoside phosphorylase inhibitors: II. Effects on nucleoside catabolism in human and rat blood in vitro
83. The biochemistry and pharmacology of PD 116124 (8-amino-2′-nordeoxyguanosine), an inhibitor of purine nucleoside phosphorylase (PNP)
84. Specificity of purine nucleoside phosphorylase from Escherichia coli
85. Enzyme catalysis in synthetic carbohydrate chemistry
86. Mechanisms of 2′-deoxyguanosine toxicity in mouse T-lymphoma cells with purine nucleoside phosphorylase deficiency and resistance to inhibition of ribonucleotide reductase by dGTP
87. Design of purine nucleoside phosphorylase inhibitors using X-ray crystallography
88. Three-dimensional structure of human erythrocytic purine nucleoside phosphorylase at 3.2 Å resolution
89. Application of crystallographic and modeling methods in the design of purine nucleoside phosphorylase inhibitors
90. Stem cells - Why wait?
91. Inherited variants of human nucleoside phosphorylase
92. Properties of PNPs from spores and vegetative cells of Bacillus cereus and their modification by orthophosphate
93. Malaria researchers wait for industry to join fight
94. Structure-based design of inhibitors of purine nucleoside phosphorylase. 3. 9-Arylmethyl derivatives of 9-deazaguanine substituted on the methylene group
95. Purine nucleoside phosphorylase: 2. Catalytic mechanism
96. Purine nucleoside phosphorylase: 1. Structure-function studies
97. Synthesis of transition state analogue inhibitors for purine nucleoside phosphorylase and N-riboside hydrolases
98. Rapid determination of purine enzyme activity in intact and lysed cells using high-performance liquid chromatography with and without radiolabelled substrates
99. Structure-activity relationships for a class of inhibitors of purine nucleoside phosphorylase
100. Bone marrow transplantation (BMT) in Europe for primary immunodeficiences other than severe combined immunodeficiency: A report from the European Group for BMT and the European Group for Immunodeficiency
101. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd
102. Adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency in common variable immunodeficiency
103. Correction of purine nucleoside phosphorylase deficiency by retroviral-mediated gene transfer in mouse S49 T cell lymphoma: A model for gene therapy of T cell immunodeficiency
104. Phosphate determination by enzymatic colorimetric assay
105. The minimal gene complement of Mycoplasma genitalium
106. Complete genome sequence of Treponema pallidum, the syphilis spirochete
107. A quantitative histochemical procedure for the demonstration of purine nucleoside phosphorylase activity in rat and human liver using Tetranitro BT and xanthine oxidase as auxiliary enzyme
108. Deoxyriboside-1-phosphate: II. The isolation of the crystalline deoxyribose-1-phosphate
109. Enzymatic synthesis of deoxyxanthosine by the action of xanthosine Phosphorylase in mammalian tissues
110. Nucleoside phosphorylases
111. Cytotoxicity, metabolism, and mechanisms of action of 2′,2′-difluorodeoxyguanosine in Chinese hamster ovary cells
112. Biochemical studies of bacterial sporulation and germination
113. Substrate specificities of 5′-deoxy-5′-methylthioadenosine phosphorylase from Trypanosoma brucei brucei and mammalian cells
114. ADA and PNP deficiencies: How it all began
115. Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity
116. Blockade of nucleoside degradation in monkey whole blood in vitro by CI-1000, a purine nucleoside phosphorylase (PNP) inhibitor
117. Enzyme cascades: Purine metabolism and immunosuppression
118. Preliminary report on 8-amino-9-(2-thienylmethyl)guanine (PD 119,229), a novel and potent purine nucleoside phosphorylase inhibitor
119. Selective in vitro inhibition of human MOLT-4 T lymphoblasts by the novel purine nucleoside phosphorylase inhibitor, CI-972
120. Biochemical and pharmacological properties of CI-972, a novel 9-deazaguanine analog purine nucleoside phosphorylase (PNP) inhibitor
121. Comparative in vitro and in vivo activities of two 9-deazaguanine analog inhibitors of purine nucleoside phosphorylase, CI-972 and PD 141955
122. Apoptotic death induced in MOLT-4 T-lymphoblasts by purine nucleoside phosphorylase inhibitors
123. Physical and catalytic properties of the purine nucleoside phosphorylase from cells and spores of Bacillus cereus T
124. Recycling of α-d-ribose-1-phosphate for nucleoside interconversion
125. Cloning of human purine nucleoside phosphorylase cDNA sequences by complementation in Escherichia coli
126. Efficacy and toxicity of 9-β-d-arabinofuranosylguanine (araG) as an agent to purge malignant T-cells from murine bone marrow: Application to an in vivo T-cell leukemia model
127. Deficient cellular immunity - Finding and fixing the defects
128. Structure-based design of inhibitors of purine nucleoside phosphorylase: 4. A study of phosphate mimics
129. Repairing the genome's spelling mistakes
130. Enzymatic determination of inorganic phosphate in the presence of creatine phosphate
131. The partial purification and characterization of purine nucleoside phosphorylase from mammalian mitochondria
132. 9-(Difluorophosphonoalkyl)guanines as a new class of multisubstrate analogue inhibitors of purine nucleoside phosphorylase
133. 9-benzylguanine as potent, slow-binding multisubstrate analogue inhibitors of purine nucleoside phosphorylase
134. Purine nucleoside phosphorylase: Purification using an ether-linked formycin B/sepharose 6B resin with unusual properties
135. Pharmacokinetics/pharmacodynamics of CI-1000, a purine nucleoside phosphorylase (PNP) inhibitor, in rats and monkeys
136. Allogeneic bone marrow transplantation corrects the immunodeficiency in PNP deficiency but does not reverse the neurological abnormalities
137. Purification and characterization of purine nucleoside phosphorylase and pyrimidine nucleoside phosphorylase from Bacillus stearothermophilus TH 6-2
138. Cloning of purine nucleoside phosphorylase II gene from Bacillus stearothermophilus TH 6-2 and characterization of its gene product
139. Cloning and expression of purine nucleoside phosphorylase I gene from Bacillus stearothermophilus TH 6-2
140. A second purine nucleoside phosphorylase in Escherichia coli K-12: II. Properties of xanthosine phosphorylase and its induction by xanthosine
141. The enzymatic synthesis of antiviral agents
142. Analytical centrifugation of complex macromolecular systems
143. A convenient synthesis of 2′-deoxy-2-fluoroadenosine; a potential prodrug for sucide gene therapy
144. A new spectrophotometric assay for enzymes of purine metabolism: III. Determination of purine nucleoside phosphorylases
145. A new method for the synthesis of nucleosides using purine nucleoside phosphorylase
146. Adenosine deaminase deficiency: Clinical expression, molecular basis, and therapy
147. Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency
148. Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol
149. Synthesis of nucleoside analogues using immobilized N-deoxyribosyltransferases
150. Complete sequence analysis of the genome of the bacterium Mycoplasma pneumoniae
151. Purification and characterization of thermostable purine nucleoside phosphorylase of Bacillus stearothermophilus JTS 859
152. Purification and characterization of second thermostable purine nucleoside phosphorylase of Bacillus stearothermophilus JTS 859
153. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: An innovative approach for cancer therapy
154. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal cells transduced with the cytosine deaminase gene: Significant antitumour effects when only a small percentage of tumour cells express cytosine deaminase
155. Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene
156. Cell to cell contact is not required for bystander cell killing by Escherichia coli purine nucleoside phosphorylase
157. PROMOTIF: A program to identify and analyze structural motifs in proteins
158. Genetic analysis of purine metabolism in Leishmania donovani
159. In vitro study of BCX-34: A new human T-lymphocyte-specific purine phosphorylase inhibitor
160. Folding and association of oligomeric and multimeric proteins
161. Purine nucleoside phosphorylase from Salmonella typhimurium and Escherichia coli. Initial velocity kinetics, ligand binding and reaction mechanism
162. Two purine nucleoside phosphorylases in Bacillus subtilis
163. Purine nucleoside phosphorylase form Salmonella typhimurium and Escherichia coli. Purification and some properties
164. Nucleotide sequence of murine purine nucleoside phosphorylase cDNA
165. Sequence and functional characterization of the human purine nucleoside phosphorylase promoter
166. Intron requirement for expression of the human purine nucleoside phosphorylase gene
167. An enhancer in the first intron of the human purine nucleoside phosphorylase-encoding gene
168. Retrovirus-mediated transduction of an engineered intron-containing purine nucleoside phosphorylase gene
169. Stereoelectronic factors in the binding of substrate analogues and inhibitors to purine nucleoside phosphorylase isolated from human erythrocytes
170. Purine nucleoside phosphorylase cleaves the C-O bond of ribose-1-phosphate. Evidence from the 18O shift in 31P NMR
171. Isolation and characterization of mutations in the Escherichia coli regulatory protein XapR
172. Differential spectrophotometry of purine compounds by means of specific enzymes: I. Determination of hydroxypurines
173. The enzymatic synthesis of purine ribosides
174. Purification and characterization of purine nucleoside phosphorylase from developing embryos of Hyalomma dromedarii
175. Sequence analysis of the genome of the unicellular cyanobacterium Synechocystis sp. strain PCC6803: II. Sequence determination of the entire genome and assignment of potential protein-coding regions
176. Complete sequence and gene organization of the genome of a hyper-thermophilic archaebacterium, Pyrococcus horikoshii OT3
177. Inhibition of purine nucleoside phosphorylase by 8-aminoguanosine: Selective toxicity for T lymphoblasts
178. 9-[(Phosphonoalkyl)benzyl]guanines. Multisubstrate analogue inhibitors of human erythrocyte purine nucleoside phosphorylase
179. [[(Guaninylalkyl)phosphinico]methyl]phosphonic acids. Mulitisubtrate analogue inhibitors of human erythrocyte purine nucleoside phosphorylase
180. Binding of phosphate and sulfate anions by purine nucleoside phosphorylase from E. coli: Ligand-dependent quenching of enzyme intrinsic fluorescence
181. Substrate/inhibitor properties of human deoxycytidine kinase (dCK) and thymidine kinases (TK1 and TK2) towards the sugar moiety of nucleosides, including O′-alkyl analogues
182. Formycin A and its N-methyl analogues, specific inhibitors E. coli of purine nucleoside phosphorylase: Induced tautomeric shifts on binding to enzyme and enzyme-ligand fluorescence energy transfer
183. Purine nucleoside phosphorylase from human erythrocytes: II. Kinetic analysis and substrate-binding studies
184. The complete genome sequence of the hyperthermophilic, sulphate-reducing archaeon Archaeoglobus fulgidus
185. Purine nucleoside phosphorylase. Inosine hydrolysis, tight binding of the hypoxanthine intermediate, and third-the-sites reactivity
186. Purine nucleoside phosphorylase. Catalytic mechanism and transition-state analysis of the arsenolysis reaction
187. Pre-steady-state transition-state analysis of the hydrolytic reaction catalyzed by purine nucleoside phosphorylase
188. Targeted gene repair
189. Gene therapy
190. Crystal structure of the calf spleen purine nucleoside phosphorylase in a complex with hypoxanthine at 2.15 Å resolution
191. Crystal structure of the ternary complex of E. coli purine nucleoside phosphorylase with formycin B, a structural analogue of the substrate inosine, and phosphate (sulphate) at 2.1 Å resolution
192. Purification and properties of inosine-guanosine phosphorylase form Escherichia coli K-12
193. Pyrimidine ribonucleoside phosphorylase activity vs. 5- and/or 6-substituted uracil and uridine analogues, including conformational aspects
194. Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleosides phosphorylase deficiency
195. Purine nucleoside phosphorylase: Kinetics, mechanism and specificity
196. Correlation of substrate stabilization patterns with proposed mechanisms for three nucleoside phosphorylases
197. Purine nucleoside synthesis, an efficient method employing nucleoside phosphorylases
198. Nucleotide analogue inhibitors of purine nucleoside phosphorylase
199. Properties of two unusual, and fluorescent substrates of purine nucleoside phosphorylase: 7-methylguanosine and 7-methylinosine
200. Antiviral acyclic nucleoside phosphonate analogues as inhibitors of purine nucleoside phosphorylase
201. The complete genome sequence of the gram-positive bacterium Bacillus subtilis
202. 6-Amino-6-methoxypurine arabinoside: An agent for T-cell malignancies
203. Investigation of alpha-deuterium kinetic isotope effects on the purine nucleoside phosphorylase reaction by the equilibrium-perturbation technique
204. Development of an assay method for purine catabolic enzymes in the mouse and its adaptation for use on an autoanalyzer
205. Rabbit brain purine nucleoside phosphorylase
206. Monomeric purine nucleoside phosphorylase from rabbit liver. Purification and characterization
207. Bovine brain purine nucleoside phosphorylase: Purification, characterization, and catalytic mechanism
208. Human erythrocyte purine nucleoside phosphorylase: Molecular weight and physical properties. A Theorell-Chance catalytic mechanism
209. Transition-state analogs as inhibitors of human and malarial hypoxanthine-guanine phosphoribosyltransferases
210. Purification and characterization of novel nucleoside phosphorylase from Klebsiella sp., its use in the enzymatic production of adenine arabinoside
211. Induction, purification and utilization of purine nucleoside phosphorylase and uridine phosphorylase from Klebsiella sp
212. Calf spleen purine nucleoside phosphorylase: Crystal structure of its ternary complex with an N(7)-acycloguanosine inhibitor and a phosphate anion
213. Properties of purine nucleoside phosphorylase from Enterobacter cloacae
214. Simultaneous assay of adenosine deaminase and purine nucleoside phosphorylase activity as possible biochemical means to detect non-Hodgkin lymphomas of the oral cavity
215. A set of independent selective markers for transfection of the human malarial parasite Plasmodium falciparum
216. The crystal structure of Escherichia coli purine nucleoside phosphorylase: A comparison with the human enzyme reveals a conserved topology
217. Calf spleen purine nucleoside phosphorylase complexed with substrates and substrate analogues
218. Purine nucleoside phosphorylase deficiency
219. Mutations in purine nucleoside phosphorylase deficiency
220. In vivo gene therapy for prostate cancer: Preclinical evaluation of two enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors
221. Ribose-1-phosphate and inosine activate uracil salvage in rat brain
222. In vitro recycling of α-d-ribose-1-phosphate for the salvage of purine bases
223. The enantioselectivity of enzymes involved in current antivirial therapy using nucleoside analogues: A new strategy?
224. Design of an adenosine phosphorylase by active-site modification of murine purine nucleoside phosphorylase
225. Mechanistic diagnoses of N-ribohydrolases and purine nucleoside phosphorylase
226. Acholeplasma laidlawii B-PG9 adenine-specific purine nucleoside phosphorylase that accepts ribose-1-phosphate, deoxyribose-1-phosphate, and xylose-1-phosphate
227. Expression of a cDNA sequence encoding human purine nucleoside phosphorylase in rodent and human cells
228. Human purine nucleoside phosphorylase and adenosine deaminase: Gene transfer into cultured cells and murine hematopoietic stem cells by using recombinant amphotropic retroviruses
229. i release following nucleotide hydrolysis in actin or tubulin assembly using 2-amino-6-mercapto-7-methylpurine ribonucleoside and purine nucleoside phosphorylase as an enzyme-linked assay
230. Acute myeloid leukemia: Correlation between purine metabolism enzyme activities and membrane immunophenotype
231. A comparison of some leucocyte differentiation markers and the adenosine deaminase and purine nucleoside phosphorylase values in B and T cell leukemias and lymphomas
232. Chronic myeloid leukemia: Correlation between purine metabolism enzyme activities and membrane immunophenotype
233. One third-the-sites transition-state inhibitors for purine nucleoside phosphorylase
234. Trypanosoma cruzi adenine nucleoside phosphorylase
235. Levels of purine nucleoside phosphorylase (PNP) as a viability marker of nonparenchymal cells in cold preserved livers
236. The highest levels of purine catabolic enzymes in mice are present in the proximal small intestine
237. Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the Escherichia coli purine nucleoside phosphorylase gene
238. Purine nucleoside phosphorylase: A target for drug design
239. Structure-based design of inhibitors of purine nucleoside phosphorylase.1. 9-(Arylmethyl) derivatives of 9-deazaguanine
240. Phosphorolytic and ribosyl transfer mechanisms of purified chicken liver purine nucleoside phosphorylase
241. Atomic structure at 2.5 Å resolution of uridine phosphorylase from E. coli as refined in the monoclinic crystal lattice
242. Characterization of purine nucleoside phosphorylase in leukemia
243. Inhibitors of the enzyme PNP as potential therapy for psoriasis
244. Synthesis and biological activity of novel class of purine nucleoside phosphorylase inhibitors
245. Gene therapy: The first decade
246. Purification and characterization of purine nucleoside phosphorylase from bovine thyroid
247. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides
248. Crystallization and some properties of purine nucleoside phosphorylase from chicken liver
249. Purine nucleoside phosphorylase of chicken liver
250. Elevated adenosine deaminase and purine nucleoside phosphorylase activity in peripheral blood null lymphocytes from patients with acquired immune deficiency syndrome
251. Unexpected sequence similarity between nucleosidases and phosphoribosyltransferases of different specificity
252. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: A review of their pharmacology and clinical potential in treatment of viral infections
253. Difference in onset of warm ischemia and reperfusion injury between parenchymal and endothelial cells of the liver. Evaluation by purine nucleoside phosphorylase and hyaluronic acid
254. Inhibition of purine nucleoside phosphorylase by phosphonoalkylpurines
255. Refined structure of purine nucleoside phosphorylase at 2.75 Å resolution
256. Correction of proliferative responses in purine nucleoside phosphorylase (PNP)-deficient T lymphocytes by retroviral-mediated PNP gene transfer and expression
257. Foamy virus vectors for suicide gene therapy
258. Purine nucleoside phosphorylase: Its use in a spectroscopic assay for inorganic phosphate and for removing inorganic phosphate with the aid of phosphodeoxyribomutase
259. Efficacy of hypothermic perfusion using University of Wisconsin solution in extended hepatectomy with hepatic inflow occlusion in a canine model
260. Construction of a 2.8-megabase yeast artificial chromosome contig and cloning of the human methylthioadenosine phosphorylase gene from the tumor suppressor region on 9p21
261. Human red cell purine nucleoside phosphorylase. Purification by biospecific affinity chromatography and physical properties
262. Design of vectors for efficient expression of human purine nucleoside phosphorylase in skin fibroblasts from enzyme-deficient humans
263. Two novel missense and frameshift mutations in exons 5 and 6 of the purine nucleoside phosphorylase (PNP) gene in a severe combined immunodeficiency (SCID) patient
264. In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase
265. Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells
266. Purine-specific nucleoside N-ribohydrolase from Trypanosoma brucei brucei
267. Purine nucleoside phosphorylase
268. Purine nucleoside phosphorylase and 5′-methylthioadenosine phosphorylase: Targets for chemotherapy
269. Purine degradative enzymes and terminal transferase in acute myelogenous leukemia: Clinical relevance
270. Cloning and characterization of mouse deoxyguanosine kinase. Evidence for a cytoplasmic isoform
271. An integrated map of the genome of the tubercle bacillus, Mycobacterium tuberculosis H37Rv, and comparison with Mycobacterium leprae
272. Purine pathway enzyme abnormalities in acute lymphoblastic leukemia
273. Purine nucleoside phosphorylase. Kinetic mechanism of the enzyme from calf spleen
274. A purine nucleoside phosphorylase (PNP) inhibitor induces apoptosis via caspase-3-like protease activity in MOLT-4 T cells
275. Nucleoside synthesis mediated by glycosyl transferring enzymes
276. Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumour-directed gene therapy
277. Purine nucleoside phosphorylase: A new marker for free oxygen radical injury to the endothelial cell
278. Reperfusion injury following cold ischemia activates rat liver Kupffer cells
279. Monitoring of acute lung rejection and infection by bronchoalveolar lavage and plasma levels of hyaluronic acid in clinical lung transplantation
280. Comparison of super-secondary structures in proteins
281. Depressed activities of purine enzymes in lymphocytes of patients infected with human immunodeficiency virus
282. Assignment of nucleoside phosphorylase to d-14 and localization of X-linked loci in men by somatic cell genetics
283. A continuous spectrophotometric assay for aspartate transcarbamylase and ATPases
284. Purification and properties of purine nucleoside phosphorylase from Salmonella typhimurium
285. Changes in monkey plasma purines induced by repeated doses of CI-1000, a novel inhibitor of purine nucleoside phosphorylase
286. Purine nucleoside phosphorylase. Allosteric regulation of a dissociating enzyme
287. Allosteric regulation of purine nucleoside phosphorylase
288. Tautomerism and ionization of xanthosine
289. Localization of purine and pyrimidine nucleoside phosphorylases in heart, kidney, and liver
290. Assay of inorganic phosphate in the mild pH range, suitable for measurement of glycogen phosphorylase activity
291. 31P NMR studies on purine nucleoside phosphorylase: Determination of the scissile bond and of the equilibrium constant
292. Relationship between the levels of purine salvage pathway enzymes and clinical/biological aggressiveness of human colon carcinoma
293. Direct evidence of autosomal recessive inheritance of Arg24 to termination codon in purine nucleoside phosphorylase gene in a family with a severe combined immunodeficiency patient
294. Rabbit erythrocyte purine nucleoside phosphorylase. Initial velocity studies
295. A designed inhibitor of base-excision DNA repair
296. Purine nucleoside phosphorylase of the malarial parasite, Plasmodium lophurae
297. Enzymatic N-ribose scission in RNA and RNA precursors
298. Enzymatic transition-state analysis and transition-state analogues
299. An enzymatic method for measurement of inorganic phosphate
300. New revolutions in the evolution of analytical ultracentrifugation
301. Structure-based design of inhibitors of purine nucleoside phosphorylase. 2. 9-Alicyclic and 9-heteroalicyclic derivatives of 9-deazaguanine
302. Gene therapy of cancer: Activation of nucleoside prodrugs with E. coli purine nucleoside phosphorylase
303. Inhibition of purine nucleoside phosphorylase by phosphonylmethylalkyl analogues of nucleotides
304. Identification and characterization of genes (xapA, xapB, and xapR) involved in xanthosine catabolism in Escherichia coli
305. A specific adenosine phosphorylase, distinct from purine nucleoside phosphorylase
306. A continuous spectrophotometric method for the determination of glycogen phosphorylase-catalyzed reaction in the direction of glycogen synthesis
307. Purine nucleoside phosphorylase from human erythrocytes: III. Inhibition by the inosine analog formycin B of the isolated enzyme and of nucleoside metabolism in intact erythrocytes and Sarcoma 180 cells
308. Potentiation of 2′-deoxyguanosine cytotoxicity by a novel inhibitor of purine nucleoside phosphorylase, 8-amino-9-benzylguanine
309. The 2.0 Å structure of malarial purine phosphoribosyltransferase in complex with a transition-state analogue inhibitor
310. Nucleoside hydrolase from Leischmania major. Cloning, expression, catalytic properties, transition state inhibitors, and the 2.5-Å crystal structure
311. Purification and properties of purine nucleoside phosphorylase from Brevibacterium acetylicum ATCC 954
312. Mechanism of 2′,3′-dideoxyadenosine synthesis by Escherichia coli AJ 2595
313. Purifications and properties of orotidine-phosphorolyzing enzyme and purine nucleoside phosphorylase from Erwinia carotovora AJ 2992
314. Production of 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine from 2′,3′-dideoxyuridine and the corresponding purine bases by resting cells of Escherichia coli AJ 2595
315. In situ removal of orthophosphate by the nucleoside phosphorylase catalyzed phosphorolysis of nicotinamide riboside
316. Phosphorylating enzymes involved in activation of chemotherapeutic nucleosides and nucleotides
317. Viral and host-cell protein kinases: Enticing antiviral targets, and relevance of nucleoside, and viral thymidine, kinases
318. Tautomerism of purines and pyrimidines, their nucleosides and various analogues
319. Purine nucleoside phosphorylase (PNP) inhibitors: Potentially selective immunosuppressive agents
320. 8-Amino-9-substituted guanines: Potent purine nucleoside phosphorylase (PNP) inhibitors
321. Inhibitors of human purine nucleoside phosphorylase. Synthesis of pyrrolo[3,2-d]pyrimidines, a new class of purine nucleoside phosphorylase inhibitors as potentially T-cell selective immunosuppressive agents. Description of 2,6-diamino-3,5-dihydro-7-(3-thienylmethyl)-4H-pyrrolo[3,2-d] pyrimidin-4-one
322. Inhibition of the enzyme purine nucleoside phosphorylase (PNP) reduces refractoriness to transfused platelets in a dog model
323. Complete genome sequence of Methanobacterium thermoautotrophicum deltaH: Functional analysis and comparative genomics
324. Secondary loss of deoxyguanosine kinase activity in purine nucleoside phosphorylase deficient mice
325. Point mutations at the purine nucleoside phosphorylase locus impair thymocyte differentiation in the mouse
326. Rational design of novel antimicrobials: Blocking purine salvage in a parasitic protozoan
327. Tumour bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines
328. Inhibition of purine nucleoside phosphorylase by acyclic nucleosides and nucleotides
329. Kinetic α-deuterium isotope effects for Escherichia coli purine nucleoside phosphorylase-catalyzed phosphorolysis of adenosine and inosine
330. Purine nucleoside phosphorylase: A target for chemotherapy
331. Purine nucleoside phosphorylase. Measurement of activity and use of inhibitors
332. Purine nucleoside phosphorylase from human erythrocytes
333. Purine nucleoside phosphorylase from human erythrocytes: Physicochemical properties of the crystalline enzyme
334. Human erythrocytic purine nucleoside phosphorylase: Reaction with sugar-modified nucleoside substrates
335. Inhibitors of purine nucleoside phosphorylase, C(8) and C(5′) substitutions
336. Design of purine nucleoside phosphorylase inhibitors
337. Inhibitors of purine nucleoside phosphorylase: Effects of 9-deazapurine ribonucleosides and synthesis of 5′-deoxy-5′-iodo-9-deazainosine
338. Purine nucleoside phosphorylase: 3. Reversal of purine base specificity by site-directed mutagenesis
339. 7-Ribosyl-3-deazaguanine - Mechanism of antibacterial action
340. An enzymatic method for determination of inorganic phosphate in serum
341. Purification and characterization of purine nucleoside phosphorylase from Proteus vulgaris
342. Molecular cloning and nucleotide sequence of purine nucleoside phosphorylase and uridine phosphorylase genes from Klebsiella sp
343. Purine nucleoside phosphorylase (PNP) from Cellulomonas sp., a different class of PNP different from both "low-molecular weight" mammalian and "high-molecular weight" bacterial PNPs
344. Crystal structures of purine nucleoside phosphorylase (PNP) from Cellulomonas sp., its implications for the molecular mechanism of trimeric PNPs
345. The complete genome sequence of the gastric pathogen Helicobacter pylori
346. Physiological concentrations of purines and pyrimidines
347. Adenine nucleoside phosphorylases in Trematode Fasciola hepatica, the mammalian parasite
348. Enzymes of the human erythrocyte: Purine nucleoside phosphorylase, specific properties
349. An association between the kinetic and electrophoretic properties of purine nucleoside phosphorylase
350. Effects of acyclovir and its metabolites on purine nucleoside phosphorylase
351. Retrovirus-mediated gene transfer in cancer chemotherapy
352. Pyrazolopyrimidine metabolism in parasitic protozoa
353. An enzymatic assay of inorganic phosphate in serum using nucleoside phosphorylase and xanthine oxidase
354. Properties of purine nucleoside phoshorylase from Enterobacter aerogenese
355. Synthesis and biological evaluation of pyrimidine and purine α-l-2′,3′-dideoxy nucleosides
356. Protein engineering of uridine phosphorylase from Escherichia coli K-12. I. Cloning and expression of uridine phosphorylase genes from Klebsiella aerogenes and Salmonella typhimurium in E. coli
357. Gene therapy - Promises, problems and prospects
358. Low enantioselectivities of human deoxycytidine kinase and human deoxyguanosine kinase with respect to 2′-deoxyadenosine, 2′-deoxyguanosine and their analogues
359. Pharmacokinetics and pharmacodynamics of peldesine (BCX-34), a purine nucleoside phosphorylase inhibitor, following single and multiple oral doses in healthy volunteers
360. BCX-34: A novel T-cell selective immunosuppressant: Purine nucleoside phosphorylase (PNP) inhibitor
361. Nucleotide sequence of the Escherichia coli uridine phosphorylase (udp) gene
362. Parasite enzymes as potential targets for antiparasitic chemotherapy
363. Stereoisomeric selectivity of human deoxyribonucleoside kinases
364. Determination of phosphate ions with an enzyme sensor system
365. Cloning and expression of human uridine phosphorylase
366. Purification, cloning, and expression of murine uridine phosphorylase
367. A continuous spectrophotometric assay for inorganic phosphate and for measuring phosphate release kinetics in biological systems
368. Interaction of GTPase-activating protein with p21ras, measured using a continuous assay for inorganic phosphate release
369. A continuous visible spectrophotometric assay for aspartate transcarbamylase
370. Potentiating effect of {2[2[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methyl]phenyl]ethenyl} phosphonic acid (MDL 74,428), a potent inhibitor of purine nucleoside phosphorylase, on the antiretrovirial activities of 2′,3′-dideoxyinosine combined to ribavirin in mice
371. Nicotinamide riboside, an unusual, non-typical, substrate of purified purine nucleoside phosphorylases
372. Cellulomonas sp. purine nucleoside phosphorylase: Comparison with human and E. coli enzymes
373. Binding of substrates by purine nucleoside phosphorylase from Cellulomonas sp.-kinetic and spectrofluorimetric studies
374. Luminescence studies of formycins, its aglycone, and their N-methyl derivatives: Tautomerism, sites of protonation and phototautomerism
375. Amino-imino tautomerism of N(6)-methylformycin, a potent inhibitor of E. coli, but not mammalian, purine nucleoside phosphorylase
376. Fluorescence emission properties of 8-azapurines and their nucleosides, and application to the kinetics of the reverse synthetic reaction of purine nucleoside phosphorylase
377. Interactions of purine nucleoside phosphorylase with antiviral acyclic nucleoside phosphonate inhibitors - Kinetic and emission studies
378. PD 141955 and CI-972: 9-deazaguanine analog purine nucleoside phosphorylase inhibitors: I. Suppression of the human mixed lymphocyte reaction (MLR)
379. Human purine nucleoside phosphorylase cDNA sequence and genomic clone characterization
380. A human purine nucleoside phosphorylase deficiency caused by a single base change
381. An in vivo and in vitro evaluation of 1-β-d-ribofuranosyl-1,2,4-triazole-3-carboxamidine: An inhibitor of human lymphoblast purine nucleoside phosphorylase
382. 2.2 Mb of contiguous nucleotide sequence from chromosome III of C. elegans
383. Subacute toxicity of a purine nucleoside phosphorylase inhibitor in rats
384. Inhibitors of human purine nucleoside phosphorylase. Synthesis and biological activities of 8-amino-3-benzylhypoxanthine and related analogues
385. Synthesis of (2′S,3′S)-O-(4′-phosphono-4′,4′- difluoro-2′,3′-methanobutyl)guanine and its enantiomer. Evaluation of the inhibitory activity for purine nucleoside phosphorylase
386. Synthesis of 1,1-difluoro-5-(1H-9-purinyl)-2-pentenylphosphonic acids and the related methano analogues. Remarkable effect of the nucleobases and the cyclopropane rings on inhibitory activity toward purine nucleoside phosphorylase
387. Synthesis and biological evaluation of 1,1-difluoro-2-(tetrahydro-3-furanyl)ethylphosphonic acids possessing a N9-purinylmethyl functional group at the ring. A new class of inhibitor for purine nucleoside phosphorylase
388. Effects of drugs on clinical laboratory tests
389. US gene therapy in crisis
390. Misuse of nonlinear Scatchard plots
391. Adenine as substrate for purine nucleoside phosphorylase
392. Kinetics and mechanism of the acid catalyzed hydrolysis of some purine nucleotides